Pharma stock soars 150% on injectables deal with Wegovy maker Novo
来源：CNBC发布于 2026-09-25
The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditio...
相关标的：NVO
本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。